Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 14/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14952248 | 0.88 | MYB (0.71) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL14952246 | 0.85 | MYB (0.67) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL5045714 | 0.84 | MYB (1.00) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL8543474 | 0.84 | MYB (0.63) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL31237908 | 0.83 | MYB (0.83) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL8538269 | 0.82 | MYB (0.76) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL14478940 | 0.82 | MYB (0.73) | MYB | |
| SCHEMBL8538804 | 0.81 | MYB (0.84) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL8542913 | 0.81 | MYB (0.74) | MYBMAPTMEN1LMNAKMT2A | |
| SCHEMBL8542892 | 0.80 | MYB (0.69) | MYBMAPTMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275174-A1 | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275174-A1 | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013070998-A1 | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275174-A1 | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES | CRBN, CCNY, CDY1; CDY1B | MYB 4845/4885MAPT 4885/4885MEN1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.